INTRODUCTION {#s1}
============

Signal transducer and activator of transcription proteins 3 (STAT3) is well demonstrated to play a crucial role in tumor development and cancer-related inflammation \[[@R1]\]. STAT3 is also linked to inflammation-related oncogenesis initiated by genetic alterations and environmental factors \[[@R2]--[@R4]\], and is constitutively activated in various cancers \[[@R5], [@R6]\]. Persistent activation of STAT3 is involved in promoting tumor cell proliferation, survival, tumor invasion, angiogenesis and immunosuppression, inducing and maintaining a pro-carcinogenic inflammatory microenvironment \[[@R7]\]. Growing studies identified novel tumor-promoting functions of STAT3 in mitochondria metabolism \[[@R8]\], drug resistance \[[@R9], [@R10]\], epigenetic regulation \[[@R11]\], cancer stem cells \[[@R12], [@R13]\] and pre-metastatic niches \[[@R14], [@R15]\]. Given the pivotal role in tumor development, STAT3 represents an attractive therapeutic target for solid tumors. Recently, accumulating studies have demonstrated STAT3-targeted therapy could effectively restrain tumor development in various solid tumors \[[@R16]--[@R21]\]. However, the prognostic value of STAT3 overexpression in human solid tumors is still controversial.

A plenty of studies showed that elevated STAT3 expression in tumor tissue was correlated with poor survival of patients with various solid tumors such as gastric cancer \[[@R22]--[@R29]\], lung cancer \[[@R30]--[@R37]\], gliomas \[[@R38]--[@R42]\], colorectal cancer \[[@R43]\], ovarian cancer \[[@R44]\], cervical cancer \[[@R45]\], hepatocellular carcinoma \[[@R46], [@R47]\], melanoma \[[@R48]\], esophageal cancer \[[@R49]\], osteosarcoma \[[@R50], [@R51]\], pancreatic cancer \[[@R52], [@R53]\], thymic epithelial tumor \[[@R54]\], astrocytomas \[[@R55]\], lingual squamous cell carcinoma \[[@R56]\], nasopharyngeal carcinoma \[[@R57]\], prostate cancer \[[@R58]\], renal cell carcinoma \[[@R59]\] and Wilms\' tumor \[[@R60]\]. However, other studies reported that overexpression of STAT3 was correlated with favorable outcome of patients with breast cancer \[[@R61]--[@R65]\], gastric cancer \[[@R66]\], lung cancer \[[@R67]--[@R69]\], colorectal cancer \[[@R70], [@R71]\] and melanoma \[[@R72]\].

Therefore, we carried out a meta-analysis combining available evidences to evaluate the prognostic value of STAT3 expression in solid tumors. We also evaluated whether the clinical outcome of patients with solid tumors differed between STAT3 phosphorylation state and between different tumor types. This meta-analysis intended to assess the role of STAT3 in relation to survival in solid tumors, thereby supporting more rational development of therapeutic strategies against STAT3.

RESULTS {#s2}
=======

Search results and study characteristics {#s2_1}
----------------------------------------

Sixty-three studies with a total of 9449 patients were included (Figure [1](#F1){ref-type="fig"}). Characteristics of included studies are shown in Table [1](#T1){ref-type="table"}. Eleven studies evaluated lung cancer \[[@R30]--[@R37], [@R67]--[@R69]\], nine evaluated gastric cancer \[[@R22]--[@R29], [@R66]\], five evaluated breast cancer \[[@R61]--[@R65]\], five evaluated gliomas \[[@R38]--[@R42]\], four evaluated colorectal cancer \[[@R43], [@R70], [@R71], [@R73]\], three evaluated ovarian cancer \[[@R44], [@R74], [@R75]\], three evaluated cervical cancer \[[@R45], [@R76], [@R77]\], two evaluated hepatocellular carcinoma \[[@R46], [@R47]\], two evaluated melanoma \[[@R48], [@R72]\], two evaluated esophageal cancer \[[@R49], [@R78]\], two evaluated osteosarcoma \[[@R50], [@R51]\], two evaluated pancreatic cancer \[[@R52], [@R53]\], two evaluated thymic epithelial tumours \[[@R54], [@R79]\], two oral cancer \[[@R80], [@R81]\], and one each evaluated astrocytomas \[[@R55]\], chordoma \[[@R82]\], head and neck squamous cell carcinoma \[[@R83]\], lingual squamous cell carcinoma \[[@R56]\], nasopharyngeal carcinoma \[[@R84]\], pharyngeal cancer \[[@R57]\], prostate cancer \[[@R58]\], renal cell carcinoma \[[@R59]\], and Wilms\' tumor \[[@R60]\]. Of these 63 studies, 20 studies evaluated STAT3, 37 studies evaluated p-STAT3, and 6 studies evaluated both STAT3 and p-STAT3. As for the region, 39 studies were conducted in Asia, 13 studies in America, 10 studies in Europe, and 1 study in Austria.
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###### Characteristics of studies included in the meta-analysis

  References                              Country    Type of cancer   Patient No.   Age, median (range)   Male/Female   Stage    Follow-Up,months (Range)   STAT3 (+/--) NO.   3-yearOS (+/--)%   5-yearOS (+/--)%   NOS Score
  --------------------------------------- ---------- ---------------- ------------- --------------------- ------------- -------- -------------------------- ------------------ ------------------ ------------------ -----------
  **Studies including OS**                                                                                                                                                                                           
  Abou-Ghazal, M., et al. (2008)          USA        Gliomas          128           44 (4--91)            NR            II-IV    NR                         65/63              36.7/48.9          34.7/41.7          7
  Ai, T., et al. (2012)                   China      NSCLC            65            NR                    50/15         I-IV     29.9 ± 15.7                47/18              49.8/77.9          NR                 8
  Birner, P., etal. (2010)                Bulgaria   Gliomas          111           58.0 ± 11.6           57/54         NR       11.1 ± 0.8                 65/46              0/17.9             NR                 7
  Chang, K. C., et al. (2006)             China      TET              118           52.7 (25--77)         65/53         I-IV     NR                         38/80              58.7/56.7          32.9/30            7
  Chatterjee, Devasis., et al. (2008)     USA        GC               143           71.1 (31--96)         75/68         IA-IV    34 (12--180)               40/103             45.1/70.1          0/60.7             8
  Chen, C. C., et al. (2010)              China      NC               95            NR                    NR            I-IV     112.8 (31.2--240)          34/61              39/61.2            31.3/53            6
  Chen, H. H., et al. (2012)              China      CC               165           69 (29--89)           0/165         I-IV     NR                         36/129             53.8/60            47.3/48.5          8
  Cortas, T., et al. (2007)               USA        NSCLC            145           70 (40--88)           64/81         I-III    35 (4--85)                 50/84              70/60.7            55.5/52            7
  Deng, J. Y., et al. (2010)              China      GC               53            55 (31--78)           37/16         I-IV     38 (2--108)                26/27              11.5/85.2          3.8/85.2           8
  Deng, J., et al. (2013)                 China      GC               114           NR                    76/38         NR       NR                         89/25              24.6/80            9.9/50.6           7
  Denley, S. M., et al. (2013)- Tyr705    UK         PDA              86            NR                    43/43         NR       22                         29/57              9/21.9             0/11               7
  Denley, S. M., et al. (2013)- Ser727    UK         PDA              86            NR                    43/43         NR       22                         30/56              83/22.2            0/11.2             7
  Dolled-F. M., et al. (2003)-M1-C        USA        BC               286           NR                    0/286         NR       NR                         198/88             94.6/87.3          85.5/80            6
  Dolled-F. M., et al. (2003)-M1-N        USA        BC               286           NR                    0/286         NR       NR                         66/220             94.6/92.1          93.1/81.2          6
  Dolled-F. M., et al. (2003)-M2-C        USA        BC               286           NR                    0/286         NR       NR                         56/229             92.5/92.5          86.7/83.7          6
  Dolled-F. M., et al. (2003)-M2-N        USA        BC               286           NR                    0/286         NR       NR                         124/161            95.7/89.9          91.3/78.7          6
  Galleges Ruiz, M. I., et al. (2009)     USA        NSCLC            178           NR                    127/51        I-III    NR                         51/111             54.5/45            48.8/36.5          7
  Gordziel, C., et al. (2013)-C           Germany    CRC              414           NR                    NR            I-III    37 (0--146)                132/282            82.8/70.6          74/61              6
  Gordziel, C., et al. (2013)-N           Germany    CRC              414           NR                    NR            I-III    37 (0--146)                124/290            78.6/72            71.2/62.1          6
  Haura, Eric B., et al. (2005)           USA        NSCLC            176           69 (45--84)           97/79         I        72 (36--108)               94/82              77.4/74.3          57.8/52.2          8
  Hbibi, A. Tadlaoui., et al. (2008)-M1   France     CRC              126           68.1                  NR            I-IV     NR                         62/38              NR                 61.3/49.2          7
  Hbibi, A. Tadlaoui., et al. (2008)-M2   France     CRC              126           68.1                  NR            I-IV     NR                         27/73              NR                 59.1/55.6          7
  Horiguchi, Akio., et al. (2002)         Japan      RCC              48            63 (24--85)           39/9          I-IV     15.9 (1--101               24/24              53.5/89.7          53.5/89.7          7
  Huang, C., et al. (2012)                China      PDA              71            67 (40--80)           50/21         I-IV     33.7 (3--60)               39/32              0/24.3             0/14.2             8
  Jia, Yanfei., et al. (2013)             China      GC               48            66 (45--83)           34/14         I-IV     NR                         19/29              54.4/86.7          12.7/47.6          7
  Kim, D. Y., et al. (2009)               Korea      GC               71            NR                    48/23         I-IV     30 (11--83)                27/44              59/86.4            40/81.8            6
  Kim, Yeon-Joo., et al. (2011)           Korea      NC               38            48 (25--74)           30/8          I-IV     43.7 (0.71--60)            10/28              NR                 41/77              8
  Kusaba, T., et al. (2006)               Japan      CRC              108           65.6 (44--86)         66/42         I-IV     NR                         62/46              61.6/90.1          48.8/90.1          8
  Lee, I., et al. (2012)                  USA        Melanoma         299           56 (13--85)           212/87        IV       NR                         236/63             44.1/41.8          22.3/25.4          7
  Lee, J., et al. (2009)                  China      GC               303           NR                    206/97        II-III   61.5 (12--134)             79/224             68.4/78.4          59.5/70.5          7
  Li, Chao., et al. (2013)                China      TET              80            46.5 (19--70)         47/33         I-IV     NR                         36/44              70.1/100           46.8/97.6          7
  Lin, G. S., et al. (2014)               China      Gliomas          90            55 (18--79).          54/36         NR       46.4 (1.2--109.6)          73/17              14/31.4            NR                 8
  Mano, Y., et al. (2013)                 Japan      HC               101           NR                    81/20         NR       NR                         36/65              71.3/84.9          60.7/84.7          8
  Min, Hao., et al. (2009)-M1             China      OC               50            50.6 (22--73)         0/50          I-IV     NR                         44/6               53.5/75.1          29/0               6
  Min, Hao., et al. (2009)-M2             China      OC               50            50.6 (22--73)         0/50          I-IV     NR                         29/21              35/88.1            0/58.7             6
  Monnien, F., et al. (2010)              France     CRC              104           66 (37--80)           76/28         NR       13 (8--48)                 39/65              82.2/78            71.8/65.5          7
  Pectasides, Eirini., et al. (2010)-1    Greece     HNSC             107           NR                    87/20         I-IV     64 (1--120)                23/47              90.4/45.9          72.4/38.3          7
  Pectasides, Eirini., et al. (2010)-2    Greece     HNSC             107           NR                    87/20         I-IV     64 (1--120)                12/25              NR                 68.8/51.4          7
  Piperi, Christina., et al. (2011)       Greece     Gliomas          97            59 (19--82)           60/37         II-IV    63 (3--180)                89/8               0/14               NR                 6
  Rosen, D. G., et al. (2006)             USA        OC               303           58.2 (20--86)         0/303         I-IV     52                         215/88             49.9/60            32.1/49.1          8
  Ryu, Keinosuke., et al. (2010)          USA        Osteosarcoma     51            20.5 (5--61)          38/13         NR       NR                         31/20              48.5/75            35.2/75            8
  Schoppmann, S. F., et al. (2012)        Austria    EC               324           63                    252/72        NR       NR                         144/180            32.6/57.6          24.9/53            7
  Sheen-Chen, et al. (2008)               China      BC               102           48.2 (26--76)         0/102         I-III    NR                         27/75              NR                 59/77.2            6
  Slinger, E., et al. (2010)              Sweden     Gliomas          21            NR                    NR            NR       NR                         7/14               0/13.6             NR                 8
  Sonnenblick, A., et al. (2012)          Israel     BC               125           NR                    0/125         NR       50                         35/90              100/91             94.4/76.6          6
  Sonnenblick, A., et al. (2013)-1        Israel     BC               375           50                    0/375         NR       NR                         47/82              97.9/96.3          94/94              7
  Sonnenblick, A., et al. (2013)-2        Israel     BC               375           50                    0/375         NR       NR                         184/150            99/91.9            94.1/80.2          7
  Takemoto, S., et al. (2009)             Japan      CC               125           47 (19--77)           0/125         I-II     NR                         71/54              80.9/96.8          78.5/94.5          7
  Tam, L., et al. (2007)-N                UK         PC               50            70 (64--73)           50/0          NR       29.5 (15--54)              22/28              72.8/92.5          57.9/84.2          8
  Tam, L., et al. (2007)-C                UK         PC               50            70 (64--73)           50/0          NR       29.5 (15--54)              19/31              58.1/100           42.5/92.7          8
  van Cruijsen, H., et al. (2009)         USA        NSCLC            164           64.5                  NR            I-III    NR                         116/48             49/58.7            33.1/50.3          7
  Wang, M., et al. (2011)                 China      NSCLC            208           59.8 (35--76)         NR            I-III    67 (1--78.2)               128/80             53.9/73.2          24.7/39.8          
  Wang, Y. C., et al. (2011)              China      Osteosarcoma     76            NR                    25/51         NR       37                         36/40              25.8/60.4          25.8/60.4          6
  Wang, Y., et al. (2011)                 China      Gliomas          68            45 (15--68)           41/27         NR       51 (1--72)                 47/21              0/15.4             NR                 7
  Woo, S., et al. (2011)                  Korea      GC               285           54.4                  193/92        I-IV     39.7 (4--84)               101/179            79/61.6            74.9/54.5          7
  Wu, Z.S., et al. (2011)                 China      Melanoma         90            NR                    52/38         I-IV     NR                         51/39              80.5/97.6          50.8/76.7          8
  Xiong, Hua., et al. (2012)-M1           China      GC               262           59.3 (23--79)         176/86        I-IV     90 (2--273)                248/14             44/64.3            28.4/42.9          8
  Xiong, Hua., et al. (2012)-M2           China      GC               262           59.3 (23--79)         176/86        I-IV     90 (2--273)                136/126            25.3/65.5          11.5/47.3          8
  Yakata, Yuichi., et al. (2007)          Japan      GC               111           68.9 (38--89)         63/48         NR       120                        55/56              37.7/83.4          37.7/78.6          8
  Yamashita, H., et al. (2006)            Japan      BC               506           NR (22--91)           0/506         NR       NR                         206/300            92/87.9            86/81.6            7
  Yang, C., et al. (2013)                 USA        OC               49            61 (41--87)           0/49          I-IV     NR                         25/24              70.6/73.4          33.5/57.6          7
  Yang, Cao., et al. (2009)               USA        Chordoma         70            59.5 (29--88)         51/19         NR       16.8 (0.8--69.2)           35/35              82.5/90.2          73.1/90.2          8
  Yin, Z., et al. (2012)                  China      NSCLC            76            NR                    48/28         I-IV     NR                         42/34              49.6/59.3          41.8/57.9          7
  Yu, Y., et al. (2015)                   China      NSCLC            82            NR                    48/34         I-IV     NR                         76/24              28.7/76.2          20.3/48.3          8
  Zhang, C. H., et al. (2012)-M1          China      HC               100           55.1 (28--77)         80/20         I-IV     15.4                       72/28              53.5/57.8          14/32.2            8
  Zhang, C. H., et al. (2012)-M2          China      HC               100           55.1 (28--77)         80/20         I-IV     15.4                       58/42              35.5/81.2          19/25.7            8
  Zhang, L. J., et al. (2013)             China      Wilms' tumor     58            31 (3--132)           38/20         I-IV     ≥ 78                       17/41              45.6/72.1          45.6/72.1          7
  Zhao, X., et al. (2012)-M1              China      SCLC             128           NR                    66/62         I-IV     67 (1--78.2)               71/57              29.7/81.6          0/9.9              7
  Zhao, X., et al. (2012)-M2              China      SCLC             128           NR                    66/62         I-IV     67 (1--78.2)               62/66              43.4/62.3          0/3.9              7
  Zhao, Yan., et al. (2012)               China      LSCC             163           NR                    NR            I-IV     NR                         100/63             75/86.7            41.8/78.6          8
  **Studies including DFS**                                                                                                                                                                                          
  Choi, Chel Hun., et al. (2010)          Korea      CC               29            NR                    0/29          I-II     NR                         20/9               49.9/84.6          49.9/84.6          8
  Lee, J., et al. (2009)                  China      GC               303           NR                    206/97        II-III   61.5 (12--134)             79/224             61.7/73.7          58.3/67.7          7
  Li, X., et al. (2015)                   China      NSCLC            164           NR                    115/40        I-III    NR                         107/57             57.4/87.6          NR                 8
  Macha, Muzafar A., et al. (2011)        Canada     Oral cancer      94            NR                    70/24         I-IV     NR                         63/31              18.6/53.9          7.1/53.9           7
  Mano, Y., et al. (2013)                 Japan      HC               101           NR                    81/20         NR       NR                         36/65              12.5/55.6          12.5/31.5          8
  Schoppmann, S. F., et al. (2012)        Austria    EC               324           63                    252/72        NR       NR                         144/180            25.8/48.3          20.2/47.2          7
  Takemoto, S., et al. (2009)             Japan      CC               125           47 (19--77)           0/125         I-II     NR                         71/54              82/97.8            78/95.3            7
  Wang, Y. C., et al. (2011)              China      Osteosarcoma     76            NR                    25/51         NR       37                         36/40              33.8/67.1          24.9/56.3          6
  Yamashita, H., et al. (2006)            Japan      BC               506           NR (22--91)           0/506         NR       NR                         206/300            83.2/74.7          72.7/65.3          7
  Zhang, L. J., et al. (2013)             China      Wilms' tumor     58            31 (3--132)           38/20         I-IV     ≥ 78                       17/41              31.4/74.1          31.4/74.1          7

M1: Marker1, STAT3; M2: Marker 2, p-STAT3; N: nuclear expression; C: cytoplasmic expression; 1: Cohort 1; 2: Cohort 2; NSCLC: Non-Small Cell Lung Cancer; GC: Gastric cancer; CRC: Colorectal Cancer; BC: Breast cancer; CC: Cervical Carcinoma; OC: Ovarian Carcinoma; PDA: Pancreatic Ductal Adenocarcinoma; TET: Thymic Epithelial Tumours; RCC: Renal Cell Carcinoma; HC: Hepatocellular Carcinoma; HNSCC: Head and Neck Squamous Cell Carcinoma; EC: Esophageal Cancer; OSCC: Oral Squamous Cell Carcinoma; SCLC: Small Cell Lung Cancer; NC: Nasopharyngeal carcinoma; LSCC: Lingual Squamous Cell Carcinoma; PC: Prostate Cancer; NR: Not Reported; DFS: disease-free survival, STAT3: Signal transducer and activator of transcription protein 3; NOS: newcastle--Ottawa Scale; OS: overall survival.

Evaluation and expression of STAT3 {#s2_2}
----------------------------------

Antibodies, detection and definition method, and cut-off values of STAT3 expression used in the included studies is summarized in Table [2](#T2){ref-type="table"}. Diverse antibodies were used for the assessment of STAT3 expression by IHC. For anti-STAT3 antibody, three studies used clone sc-8019, one study each used clone RB-9237, F-2, sc-7179, 79D7, 124H6, and sixteen studies did not report the antibody clone. For anti-p-STAT3 antibody, eight studies used clone D3A7, four studies used clone sc-7993, two studies used clone 9131, one study each used sc-483, sc-8001, sc-8059, ZP-0647, and twenty studies did not report the antibody clone. The median expression of STAT3 in solid tumors was 47.79%, range from 19.65% to 94.66%.

###### Evaluation of human STAT3/p-STAT3 by IHC in the selected studies

  References                                Type of cancer   Marker                Cutoff                                              Antibody (Clone)
  ----------------------------------------- ---------------- --------------------- --------------------------------------------------- -----------------------------------------------------------
  Abou-Ghazal, M., et al. (2008)            Gliomas          p-STAT3               NR                                                  anti-p-STAT3 (Tyr705), Cell Signaling Technology
  Ai, T., et al. (2012)                     NSCLC            STAT3                 IHC \> 51%                                          anti-STAT3, Cell Signaling Technology
  Birner, P., etal. (2010)                  Gliomas          p-STAT3               IHC ≥ 5%                                            anti-p-STAT3 (Tyr705), clone D3A7, Cell Signaling
  Chang, K. C., et al. (2006)               TET              STAT3                 IHC ≥ 10%                                           anti-Stat3 F-2: sc-8019, Santa Cruz Biotechnology, Inc.
  Chatterjee, Devasis., et al. (2008)       GC               STAT3-nuclear         IHC scores ≥ 4                                      anti-STAT3, Santa Cruz Biotechnology, Inc.
  Chen, H. H., et al. (2012)                CC               STAT3                 IHC ≥ 20%                                           anti-STAT3, Santa Cruz Biotechnology, Inc.
  Chen, C. C., et al. (2010)                NC               p-STAT3               IHC \> 10%                                          NR
  Choi, Chel Hun., et al. (2010)            CC               p-STAT3               IHC \> 51%                                          anti-p-STAT3 (ser727), Santa Cruz Biotechnology
  Cortas, T., et al. (2007)                 NSCLC            p-STAT3               IHC ≥ 5%                                            anti-p-STAT3 (sc-8059), Santa Cruz Biotechnology
  Deng, J. Y., et al. (2010)                GC               p-STAT3               ≥ 10%                                               anti-p-STAT3 (sc-483)
  Deng, J., et al. (2013)                   GC               p-STAT3               IHC \> 25%                                          anti-p-STAT3, Santa, sc-8001-R
  Denley, S. M., et al. (2013)              PDA              p-STAT3               IHC ≥ 2%                                            anti-pStat3 Tyr 705, 9131, Cell Signaling Technology
                                                                                                                                       anti-pStat3 (Ser 727), 9134, Cell Signaling Technology
  Dobi, E., et al. (2013)                   CRC              p-STAT3               IHC \> 15%                                          anti-p-STAT3, sc-7993, Santa Cruz Biotechnology
  Dolled-Filhart, M., et al. (2003)         BC               STAT3-cytoplasmic     IHC score ≥ 1                                       anti-STAT3, Cell Signaling Technology
                                                             STAT3-nuclear         anti-STAT3, Cell Signaling Technology               
                                                             p-STAT3-cytoplasmic   anti-p-STAT3 (Tyr 705), Cell Signaling Technology   
                                                             p-STAT3-nuclear       anti-p-STAT3 (Tyr 705), Cell Signaling Technology   
  Galleges Ruiz, M. I., et al. (2009)       NSCLC            p-STAT3-nuclear       IHC score \> 210                                    anti--p-STAT3
  Gordziel, C., et al. (2013)               CRC              STAT3-cytoplasmic     IHC score ≥ 2                                       anti-STAT3: Stat3 (79D7), Cell Signaling Technology
                                                             STAT3-nuclear                                                             
  Haura, Eric B., et al. (2005)             NSCLC            p-STAT3-nuclear       IHC score ≥ 1                                       anti-p-Stat3 (Tyr 705), Cell Signaling Technology
  Hbibi, A. Tadlaoui., et al. (2008)        CRC              p-STAT3               IHC score ≥ 6                                       anti-P-STAT3 (Tyr 705), Cell Signaling Technology
                                                             STAT3                                                                     anti-STAT3, Cell Signaling
  Horiguchi, Akio., et al. (2002)           RCC              p-STAT3               IHC ≥ 10%                                           anti-p-STAT3, (Tyr 705), Cell Signaling Technology
  Huang, C., et al. (2012)                  PDA              p-STAT3               IHC ≥ 25%                                           anti-p-STAT3, Cell Signaling Technology
  Jia, Yanfei., et al. (2013)               GC               STAT3                 NR                                                  anti-STAT3, Santa Cruz Biotechnology
  Kim, D. Y., et al. (2009)                 GC               STAT3                 NR                                                  anti-STAT3, Chemicon International
  Kim, Yeon-Joo., et al. (2011)             NC               STAT3                 IHC ≥ 10%                                           anti-STAT3, Epitomics
  Kusaba, T., et al. (2006)                 CRC              p-STAT3               IHC \> 15%                                          anti-p-STAT3 (Tyr705), Santa Cruz Biotechnology
  Lee, I., et al. (2012)                    Melanoma         p-STAT3               IHC ≥ 1%                                            anti-p-STAT3 (Tyr705), Santa Cruz Biotechnology
  Lee, J., et al. (2009)                    GC               p-STAT3               IHC ≥ 1%                                            anti-p-STAT3 (Tyr705), Cell Signaling Technology
  Li, Chao., et al. (2013)                  TET              STAT3                 IHC \> 10%                                          anti-STAT3, Santa Cruz Biotechnology
  Li, X., et al. (2015)                     NSCLC            STAT3                 IHC score ≥ 4                                       anti-STAT3, Santa Cruz Biotechnology
  Lin, G. S., et al. (2014)                 Gliomas          p-STAT3               IHC \> 5%                                           anti-p-STAT3 (Tyr705), D3A7, Cell Signaling
  Macha, Muzafar A., et al. (2011)          Oral cancer      p-STAT3               NR                                                  anti-p-STAT3 (Tyr 705), Cell Signaling
  Mano, Y., et al. (2013)                   HC               p-STAT3               NR                                                  anti-p-STAT3 (Tyr 705), D3A7, Cell Signaling
  Min, Hao., et al. (2009)                  OC               STAT3                 IHC ≥ 10%                                           anti-Stat3, (SC-8019), Santa Cruz Biotechnology
                                                             p-STAT3               IHC ≥ 10%                                           anti-p-Stat3 (Tyr 705), ZP-0647, Abzoom Biotechnology
  Monnien, F., et al. (2010)                CRC              p-STAT3               IHC \> 15%                                          anti-p-Stat3 (Tyr 705), sc-7993, Santa Cruz
  Pectasides, Eirini., et al. (2010)        HNSCC            STAT3-nuclear         NR                                                  anti-Stat3, clone 124H6; Cell Signaling Technology
  Piperi, Christina., et al. (2011)         Gliomas          p-STAT3               IHC ≥ 6%                                            anti-p-STAT3 (Tyr 705), D3A7 XP, Cell Signaling
  Rosen, D. G., et al. (2006)               OC               p-STAT3               IHC \> 10%                                          anti-p-Stat3, (SC-7993-R), Santa Cruz Biotechnology
  Ryu, Keinosuke., et al. (2010)            Osteosarcoma     p-STAT3               IHC \> 51%                                          anti-p-STAT, Cell Signaling Technology
  Schoppmann, Sebastian F., et al. (2012)   EC               p-STAT3               IHC \> 10%                                          anti-p-STAT3 (Tyr 705), D3A7, Cell Signaling
  Shah, N. G., et al. (2006)                OSCC             STAT3-nuclear         IHC \> 10%                                          anti-STAT3, Santa Cruz Biotechnology
  Slinger, E., et al. (2010)                Gliomas          p-STAT3               IHC \> 30%                                          anti-p-STAT3, (Tyr 705), Cell Signaling
  Sheen-Chen, Shyr-Ming., et al. (2008)     BC               STAT3                 IHC score ≥ 3                                       anti-STAT3 (RB-9237), NeoMarkers
  Sonnenblick, A., et al. (2012)            BC               p-STAT3               IHC ≥ 25%                                           anti-p-STAT3, (Tyr 705), Cell Signaling
  Sonnenblick, A., et al. (2013)            BC               p-STAT3               IHC ≥ 10%                                           anti-p-STAT3, (Tyr 705), Cell Signaling
  Takemoto, S., et al. (2009)               CC               p-STAT3               IHC ≥ 5%                                            anti-p-Stat3 (Tyr 705), sc-7993, Santa Cruz Biotechnology
  Tam, L., et al. (2007)                    PC               p-STAT3-cytoplasmic   ICCC \> 0.7                                         anti-p-STAT3 (Tyr 705), 9131, Cell Signaling
                                                             p-STAT3-nuclear                                                           
  van Cruijsen, H., et al. (2009)           NSCLC            p-STAT3               NR                                                  anti-p-STAT3 (Tyr 705), clone D3A7, Cell Signaling
  Wang, M., et al. (2011)                   NSCLC            p-STAT3               IHC \> 25%                                          anti-p-STAT3, Cell Signaling Technology
  Wang, Y., et al. (2011)                   Gliomas          p-STAT3               IHC score \> 4                                      anti-p-STAT3 (Tyr 705), clone D3A7, Cell Signaling
  Wang, Y. C., et al. (2011)                Osteosarcoma     STAT3                 IHC \> 5%                                           anti-STAT3, Santa Cruz Biotechnology
  Wu, Zheng-Sheng., et al. (2011)           Melanoma         p-STAT3               NR                                                  anti-p-STAT3, Santa Cruz Biotechnology
  Woo, S., et al. (2011)                    GC               p-STAT3               IHC ≥ 1%                                            anti-p-STAT3, (Tyr 705), Cell Signaling
  Xiong, Hua., et al. (2012)                GC               STAT3                 IHC \> 15%                                          anti-STAT3
                                                             p-STAT3                                                                   anti-p-STAT3 (Tyr 705)
  Yakata, Yuichi., et al. (2007)            GC               p-STAT3               IHC \> 10%                                          anti-p-STAT3, Santa Cruz Biotechnology
  Yamashita, H., et al. (2006)              BC               STAT3                 IHC score ≥ 2                                       anti-STAT3, (F-2), Santa Cruz Biotechnology
  Yang, C., et al. (2013)                   OC               p-STAT3               IHC \> 50%                                          anti-p-STAT3, (Tyr 705), Cell Signaling Technology
  Yang, Cao., et al. (2009)                 Chordoma         p-STAT3               IHC score ≥ 4                                       anti-p-STAT3, Cell Signaling Technology
  Yin, Z., et al. (2012)                    NSCLC            STAT3                 IHC ≥ 50%                                           anti-STAT3, (sc-8019); Santa Cruz
  You, Z., et al. (2012)                    EC               p-STAT3               IHC score ≥ 2                                       anti-p-STAT3, (Tyr 705), Cell Signaling Technology
  Yu, Y., et al. (2015)                     NSCLC            pSTAT3                IHC score ≥ 3                                       NR
  Zhang, C. H., et al. (2012)               HC               STAT3                 IHC \> 10%                                          anti-STAT3, Santa Cruz Biotechnology
                                                             p-STAT3                                                                   anti-p-STAT3, (Tyr 705), Cell Signaling Technology
  Zhang, L. J., et al. (2013)               Wilms\' tumor    STAT3                 IHC \> 51%                                          anti-STAT3, (sc-7179), Santa Cruz Biotechnology
  Zhao, X., et al. (2012)                   SCLC             STAT3                 IHC ≥ 25%                                           anti-STAT3, Wuhan Boster Company
                                                             p-STAT3                                                                   anti-p-STAT3, clone B-7, Wuhan Boster Company
  Zhao, Yan., et al. (2012)                 LSCC             STAT3                 IHC ≥ 10%                                           anti-STAT3, Santa Cruz Biotechnology

NSCLC: Non-Small Cell Lung Cancer; GC: Gastric cancer; CRC: Colorectal Cancer; BC: Breast cancer; CC: Cervical Carcinoma; OC: Ovarian Carcinoma; PDA: Pancreatic Ductal Adenocarcinoma; TET: Thymic Epithelial Tumours; RCC: Renal Cell Carcinoma; HC: Hepatocellular Carcinoma; HNSCC: Head and Neck Squamous Cell Carcinoma; EC: Esophageal Cancer; OSCC: Oral Squamous Cell Carcinoma; SCLC: Small Cell Lung Cancer; NC: Nasopharyngeal carcinoma; LSCC: Lingual Squamous Cell Carcinoma; PC: Prostate Cancer; ICCH: Interclass Correlation Coefficient; NR: Not Reported.

Association of STAT3 with OS {#s2_3}
----------------------------

The combined analysis of 54 studies showed that STAT3 overexpression in tumor tissue was associated with worse 3-year OS of solid tumors (OR = 2.06, 95% CI = 1.57 to 2.71, *P* \< 0.00001) (Figure [2](#F2){ref-type="fig"}). There was significant heterogeneity among studies (Cochran\'s Q *P* \< 0.00001, I^2^ = 81%), so we conducted meta-regression analysis and subgroup meta-analysis to investigate the possible source of the heterogeneity among studies.

![Three-year overall survival (OS) by STAT3 expression\
M1: Marker 1, STAT3; M2: Marker 2, p-STAT3; 1: Cohort 1; 2: Cohort 2; N: nuclear expression; C: cytoplasmic expression.](oncotarget-07-19863-g002){#F2}

In the stratified analysis by tumor types, STAT3 expression was associated with worse 3-year OS of gastric cancer (OR = 4.06, 95% CI = 1.86 to 8.89, *P =* 0.0004), lung cancer (OR = 2.22, 95% CI = 1.31 to 3.77, *P =* 0.003), gliomas (OR = 4.10, 95% CI = 1.50 to 11.23, *P =* 0.006), hepatic cancer (OR = 3.75, 95% CI = 1.71 to 8.21, *P =* 0.001), osteosarcoma (OR = 3.94, 95% CI = 1.83 to 8.51, *P =* 0.0005) and prostate cancer (OR = 11.08, 95% CI = 1.24 to 98.96, *P =* 0.03) (Figure [3](#F3){ref-type="fig"}). There was no significant association between STAT3 expression and 3-year OS of colorectal cancer, ovarian cancer, pancreatic cancer, cervical cancer, melanoma and thymic epithelial tumor ([Supplementary Figure S1](#SD1){ref-type="supplementary-material"}). Interestingly, STAT3 overexpression was associated with favorable 3-year OS of breast cancer (OR = 0.51, 95% CI = 0.35 to 0.74, *P =* 0.0004) ([Supplementary Figure S2](#SD1){ref-type="supplementary-material"}).

![Subgroup analysis of 3-year OS by STAT3 expression in different tumor types\
(**A**) gastric cancer; (**B**) lung cancer; (**C**) gliomas; (**D**) hepatic cancer; (**E**) osteosarcoma; (**F**) prostate cancer. M1: Marker 1, STAT3; M2: Marker 2, p-STAT3; 1: Cohort 1; 2: Cohort 2 N: nuclear expression; C: cytoplasmic expression.](oncotarget-07-19863-g003){#F3}

Meta-regression analysis showed that publication year, country, gender and NOS score did not contribute to the heterogeneity (data not shown).

Analysis of 49 studies showed STAT3 expression was also associated with worse 5-year OS (OR = 2.00, 95% CI = 1.53 to 2.63, *P* \< 0.00001) (Figure [4](#F4){ref-type="fig"}) of solid tumors. There was also high heterogeneity among studies for 5-year OS (Cochran\'s Q *P* \< 0.00001, I^2^ = 82%), so we conducted subgroup meta-analysis.

![Five-year OS by STAT3 expression\
M1: Marker 1, STAT3; M2: Marker 2, p-STAT3; 1: Cohort 1; 2: Cohort 2 N: nuclear expression; C: cytoplasmic expression.](oncotarget-07-19863-g004){#F4}

Subgroup analysis showed that STAT3 expression was associated with worse 5-year OS of gastric cancer (OR = 5.48, 95% CI = 2.14 to 14.01, *P =* 0.0004), hepatic cancer (OR = 2.48, 95% CI = 1.41 to 4.35, *P =* 0.002), osteosarcoma (OR = 4.84, 95% CI = 2.23 to 10.50, *P* \< 0.0001), pancreatic cancer (OR = 9.71, 95% CI = 1.80 to 52.41, *P =* 0.008) and prostate cancer (OR = 8.35, 95% CI = 1.81 to38.51, *P =* 0.007) (Figure [5](#F5){ref-type="fig"}). There was no significant association between STAT3 expression and the 5-year OS of colorectal cancer, lung cancer, ovarian cancer, cervical cancer, melanoma and thymic epithelial tumor ([Supplementary Figure S3](#SD1){ref-type="supplementary-material"}). STAT3 overexpression was associated with favorable 5-year OS of breast cancer (OR = 0.57, 95% CI = 0.37 to 0.89, *P =* 0.01) ([Supplementary Figure S4](#SD1){ref-type="supplementary-material"}).

![Subgroup analysis of 5-year OS by STAT3 expression in different tumor types\
(**A**) gastric cancer; (**B**) hepatic cancer; (**C**) osteosarcoma; (**D**) pancreatic cancer; (**E**) prostate cancer. M1: Marker 1, STAT3; M2: Marker 2, p-STAT3; 1: Cohort 1; 2: Cohort 2 N: nuclear expression; C: cytoplasmic expression.](oncotarget-07-19863-g005){#F5}

Twenty studies evaluated STAT3, 38 studies evaluated p-STAT3 and 5 studies evaluated both STAT3 and p-STAT3. Our result showed that both STAT3 and p-STAT3 overexpression were associated with worse OS of solid tumors. However, elevated p-STAT3 (OR = 2.45, 95% CI = 1.73 to 3.46, *P* \< 0.00001) expression in tumor tissue seemed to be more significantly associated with worse 3-year OS than STAT3 expression (OR = 1.72, 95% CI = 1.10 to 2.70, *P =* 0.02) ([Supplementary Figure S5](#SD1){ref-type="supplementary-material"}). Similar result was observed for 5-year OS analysis ([Supplementary Figure S6](#SD1){ref-type="supplementary-material"}). A subgroup meta-analysis of studies evaluated both STAT3 and p-STAT3 shown that p-STAT3 expression was associated with worse 3-year and 5-year OS of solid tumor, but not STAT3 ([Supplementary Figure S7](#SD1){ref-type="supplementary-material"}).

We also evaluated the correlation between STAT3 overexpression and the TNM stage of tumor. High expression level of STAT3 was significantly associated with advanced TNM stage (OR = 0.42, 95% CI = 0.31 to 0.58, *P* \< 0.00001) (Figure [6](#F6){ref-type="fig"}).

![Subgroup analysis the correlation of STAT3 expression and tumor stage\
M1: Marker 1, STAT3; M2: Marker 2, p-STAT3.](oncotarget-07-19863-g006){#F6}

Next, we conducted subgroup analysis according to STAT3 expression level. Results showed STAT3 expression was associated with poor 3-year OS in the studies using cutoff values of 10%--30% (OR = 3.61, 95% CI = 2.42 to 5.39, *P* \< 0.00001) and 50% (OR = 2.14, 95% CI = 1.29 to 3.57, *P =* 0.003) (Figure [7](#F7){ref-type="fig"}) to determine STAT3 positivity. Similar result was observed in 5-year OS ([Supplementary Figure S6](#SD1){ref-type="supplementary-material"}). However, the studies used cutoff value of STAT3 overexpression as more than 1%-6% tumor cells positive was not associated with 3-year and 5-year OS of solid tumors.

![Subgroup analysis the correlation between STAT3 overexpression and 3-year OS of solid tumors according to cut-off values determining STAT3 positivity\
M1: Marker 1, STAT3; M2: Marker 2, p-STAT3.](oncotarget-07-19863-g007){#F7}

Association of STAT3 with DFS {#s2_4}
-----------------------------

Meta-analysis of 10 studies showed that STAT3 expression was associated with statistically significant poor 3-year DFS (OR = 3.52, 95% CI = 1.85 to 6.71, *P =* 0.0001) (Figure [8A](#F8){ref-type="fig"}) and poor 5-year DFS (OR = 3.37, 95% CI = 1.67 to 6.80, *P =* 0.0007) (Figure [8B](#F8){ref-type="fig"}).

![Three and five-year DFS by STAT3 expression\
(**A**) 3-year DFS; (**B**) 5-year DFS. M1: Marker 1, STAT3; M2: Marker 2, p-STAT3.](oncotarget-07-19863-g008){#F8}

Sensitivity analyses {#s2_5}
--------------------

Removal of the studies that was an outlier (score, IRS, \> 50% vs 1%--6% for other studies) or no report (NR) with regard to the cutoff of STAT3 overexpression by IHC did not influence results for 3- or 5-year OS (OR = 2.45, 95% CI = 1.73 to 3.48, *p* \< 0.00001; OR = 2.08, 95% CI = 1.46 to 2.96, *p* \< 0.0001; respectively). Exclusion of these studies did not reduce heterogeneity for 3- or 5-year OS (Cochran\'s Q *P* \< 0.00001, I^2^ = 82%; Cochran\'s Q *P* \< 0.00001, I^2^ = 84%, respectively).

Removal of studies with NOS score 6 did not influence results for 3- or 5-year OS (OR = 2.49, 95% CI = 1.86 to 3.34, *p* \< 0.00001; OR = 2.33, 95% CI = 1.74 to 3.12, *p* \< 0.00001, respectively). Exclusion of these studies did not reduce heterogeneity for 3- or 5-year OS (Cochran\'s Q *P* \< 0.00001, I^2^ = 80%; Cochran\'s Q *P* \< 0.00001, I^2^ = 82%, respectively).

Publication bias {#s2_6}
----------------

Funnel plot analysis showed that there was no statistical evidence of publication bias in our meta-analysis (data not shown).

DISCUSSION {#s3}
==========

This meta-analysis is the most comprehensive assessment of the literatures regarding STAT3 expression and tumor prognosis to date. We systematically evaluated survival data for 9449 solid tumor patients included in 63 different studies. Our study demonstrated that the expression of STAT3 is a marker of poor prognosis in solid tumors, with consistent results of OS at 3 and 5 years. Regarding to the tumor types, elevated STAT3 expression in tumor tissues were associated with worse OS of gastric cancer, lung cancer, gliomas, hepatic cancer, osteosarcoma, prostate cancer and pancreatic cancer. However, elevated STAT3 expression was associated with better prognosis of breast cancer. In addition, expression level of phosphorylated STAT3 was more significantly associated with worse outcome of solid tumors than unphosphorylated STAT3.

Our study found there is no significant correlation between STAT3 overexpression and OS of colorectal cancer and ovarian cancer. And STAT3 overexpression in breast cancer tissue is associated with favorable OS. However, recent studies demonstrated that STAT3-targeted inhibitor could restrain tumor development in various solid tumor models including breast cancer \[[@R16], [@R19], [@R85], [@R86]\], melanoma \[[@R87]\] and ovarian cancer \[[@R16], [@R88]\]. These divergences suggest that further study is needed to shed more light on the underling mechanism of STAT3 signal pathway in pro-tumor microenvironment in different tumor types.

There are several important implications in this meta-analysis. First, it shows that STAT3 expression is related to adverse outcome of most solid tumors. Second, it identifies a subgroup of tumors with unfavorable outcome in gastric cancer, lung cancer, hepatic cancer, prostate cancer and glioblastoma, but with favorable outcome in breast cancer. Finally, it emphasizes the potential of STAT3 to developing a valuable therapeutic target and prognostic biomarker for solid tumor.

This study also has some limitations. First, from the literature we could only extract summarized population-level data rather than individual patient-level data. Second, the method for assessing STAT3 expression and definition of STAT3 positivity are inconsistent. Finally, substantial heterogeneity observed across included studies cannot be fully accounted for by our use of appropriate meta-analytic techniques with random-effects modeling.

In summary, STAT3 expression in solid tumor tissues is associated with poor survival in most solid tumors, which suggests that STAT3 is a valuable prognostic biomarker and a promising therapeutic target for solid tumors.

MATERIALS AND METHODS {#s4}
=====================

This meta-analysis was conducted according to the statement for reporting systematic reviews and meta-analyses \[[@R89]\]. This study summarized and analyzed the results of previous studies, so the ethical approval was not necessary.

Search strategy and study selection {#s4_1}
-----------------------------------

An electronic search of Pubmed, Web of Science and EBSCO were undertaken for studies evaluating STAT3 or p-STAT3 expression and clinical outcome in solid tumors from 1994 to August 2015. The search was performed with subject heading terms including "signal transducer and activator of transcription 3" or "STAT3 transcription factor" or "STAT3" or "phosphorylated signal transducer and activator of transcription 3" or "phosphorylated STAT3 transcription factor" or "phospho-STAT3" and "neoplasms" and the results were limited to human studies of solid tumors. In addition, the entry "signal transducer and activator of transcription 3" or "STAT3 transcription factor" or "STAT3" or "phosphorylated signal transducer and activator of transcription 3" or "phosphorylated STAT3 transcription factor" or "phospho-STAT3" and the name of each specific solid tumor were used for additional studies. A total of 3547, 3542 and 2914 entries were identified, respectively. Inclusion criteria were the measurement of STAT3 and (or) p-STAT3 by immunohistochemistry (IHC), availability of survival data for at least 3 years, and original article written in English. Exclusion criteria were studies evaluating gene expression of STAT3 measured by polymerase chain reaction (PCR) and STAT3 expression in lymph node and myeloid cells. Citation lists of retrieved articles were manually screened to ensure sensitivity of the search strategy. Study selection was based on the association of STAT3 and survival. Two reviewers (Pin Wu and Dang Wu) evaluated independently all of the full articles for study eligibility. Inter-reviewer agreement was assessed using Cohen\'s kappa coefficient. Disagreement was resolved by consensus.

Data extraction {#s4_2}
---------------

Overall survival (OS) and disease free survival (DFS) were the primary endpoints of interest. Data were extracted using predefined abstraction forms. The following details were extracted by two authors (Pin Wu and Dang Wu): name of first author, year of publication, country of publication, tumor type, patient number, tumor stage, antibodies used for the evaluation, method and score for STAT3 assessment, and cut-off values to determine STAT3 positivity. Data for 3 and 5 year of OS and DFS were extracted from tables or Kaplan--Meier curves for both STAT3 negative and STAT3 positive group.

The studies included in our meta-analysis were all cohort studies. Two independent authors evaluated the quality of each included study using Newcastle-Ottawa Scale (NOS) \[[@R90]\]. The studies with 6 scores or more were considered as high quality studies. A consensus NOS score for each item was achieved finally.

Data synthesis {#s4_3}
--------------

The relative frequency of OS and DFS at 3 and 5 years between STAT3 negative and STAT3 positive group was presented as an odds ratio (OR) and its 95% confidence interval (CI). Sensitivity analyses were carried out for different analytical methods and cut-offs for defining STAT3 expression and NOS scores for quality assessment of included studies. Publication bias was assessed by visual inspection of the funnel plot.

Statistical analysis {#s4_4}
--------------------

Data were extracted from the primary publications and combined into a meta-analysis using RevMan 5.3 analysis software (Cochrane Collaboration, Copenhagen, Denmark). Estimates of ORs were weighted and pooled using the Mantel--Haenszel random effect model. Statistical heterogeneity was assessed using the Cochran\'s Q and I^2^ statistics. Differences between subgroups were assessed using methods as previous described by Deeks et al. \[[@R91]\]. Meta-regression analysis was conducted using Stata 12.0 software (StataCorp LP, College Station, TX). All statistical tests were two-sided, and statistical significance was defined as P less than 0.05. No correction was made for multiple statistical testing.
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